GOOGLE’S AI DRUG LAB RAISES $2 BILLION — THE RACE TO CURE DISEASES WITH ALGORITHMS HEATS UP Isomorphic Labs — the AI drug discovery spin-off from Google DeepMind that cracked protein-folding puzzles that stumped scientists for 50 years — is now raising more than $2 billion in a new funding round led by Thrive Capital, with Alphabet itself throwing in more cash. This is the company that already has partnerships with Eli Lilly and Novartis to design drug candidates using AI, meaning your future cancer treatment may literally be engineered by a neural network. The pharmaceutical industry, which moves at geological speed, is about to be dragged into the AI era by the scruff of its white lab coat. Keywords: Isomorphic Labs, AI drug discovery, Google DeepMind, biotech AI funding, AlphaFold